356 related articles for article (PubMed ID: 20579598)
1. Clinical update on graft-versus-host disease in children.
Goddard DS; Horn BN; McCalmont TH; Cordoro KM
Semin Cutan Med Surg; 2010 Jun; 29(2):92-105. PubMed ID: 20579598
[TBL] [Abstract][Full Text] [Related]
2. The changing face of graft-versus-host disease.
Schaffer JV
Semin Cutan Med Surg; 2006 Dec; 25(4):190-200. PubMed ID: 17174839
[TBL] [Abstract][Full Text] [Related]
3. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Optimal management of chronic graft-versus-host disease in children.
Jacobsohn DA
Br J Haematol; 2010 Aug; 150(3):278-92. PubMed ID: 20553274
[TBL] [Abstract][Full Text] [Related]
6. Life-threatening graft-vs-host disease.
Vargas-Díez E; García-Díez A; Marín A; Fernández-Herrera J
Clin Dermatol; 2005; 23(3):285-300. PubMed ID: 15896544
[TBL] [Abstract][Full Text] [Related]
7. Initial liver involvement in acute GVHD is predictive for nonrelapse mortality.
Robin M; Porcher R; de Castro R; Fisher G; de Latour RP; Ribaud P; Petropoulou AD; Rocha V; Devergie A; Mary JY; Socié G
Transplantation; 2009 Nov; 88(9):1131-6. PubMed ID: 19898210
[TBL] [Abstract][Full Text] [Related]
8. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children.
Kondo M; Kojima S; Horibe K; Kato K; Matsuyama T
Bone Marrow Transplant; 2001 Apr; 27(7):727-30. PubMed ID: 11360113
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
[TBL] [Abstract][Full Text] [Related]
11. Chronic graft-versus-host disease: clinical manifestation and therapy.
Ratanatharathorn V; Ayash L; Lazarus HM; Fu J; Uberti JP
Bone Marrow Transplant; 2001 Jul; 28(2):121-9. PubMed ID: 11509929
[TBL] [Abstract][Full Text] [Related]
12. An overview of chronic oral graft-vs-host disease following pediatric hematopoietic stem cell transplantation.
da Fonseca MA; Hong C
Pediatr Dent; 2008; 30(2):98-104. PubMed ID: 18481573
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of chronic graft-versus-host disease.
Gilman AL; Serody J
Semin Hematol; 2006 Jan; 43(1):70-80. PubMed ID: 16412791
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
15. GVHD pathophysiology: is acute different from chronic?
Toubai T; Sun Y; Reddy P
Best Pract Res Clin Haematol; 2008 Jun; 21(2):101-17. PubMed ID: 18503979
[TBL] [Abstract][Full Text] [Related]
16. [A method for modeling skin explants--an in vitro predictive test for graft vs host disease in allogenic hematopoietic cell transplantation].
Hromadníková I; Sedlácek P; Starý J; Vavrinec J; Cermáková-Frantlová M; Stechová K; Houbová B; Vítek A; Sajdová J; Sviland L; Dickinson AM
Cas Lek Cesk; 2001 Feb; 140(3):73-8. PubMed ID: 11284422
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.
Goldberg J; Jacobsohn DA; Zahurak ML; Vogelsang GB
Biol Blood Marrow Transplant; 2005 Feb; 11(2):101-7. PubMed ID: 15682070
[TBL] [Abstract][Full Text] [Related]
18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease: review and nursing implications.
Mattson MR
Clin J Oncol Nurs; 2007 Jun; 11(3):325-8. PubMed ID: 17623617
[TBL] [Abstract][Full Text] [Related]
20. Many faces of graft-versus-host disease.
Peñas PF; Zaman S
Australas J Dermatol; 2010 Feb; 51(1):1-10; quiz 11. PubMed ID: 20148830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
